The pharmaceutical supply chain is a complex, multi-tiered network that historically has been optimized for efficiency and cost reduction above […]
Pharmaceutical Supply Chain Resilience: Lessons from the Pandemic Read Post »
Investors and executives often treat the expiration of a composition-of-matter patent as the singular moment of truth in a drug’s
The 1,825-day head start: How to stop a generic without a patent Read Post »
The strategic landscape of the modern pharmaceutical and biotechnology industries is bifurcated by two distinct regulatory and legal architectures that
The regulatory framework of the United States pharmaceutical industry is governed by a complex interplay of scientific evaluation, legislative compromise,
The pharmaceutical landscape in the United States is currently defined by a paradox: a system designed to foster innovation has
Economic success in the generic pharmaceutical industry depends on timing. Between 2026 and 2030, blockbuster drugs representing an estimated $236
The 180-Day Prize: Using Orange Book Patent Data to Secure Early Market Control Read Post »
The 20-year patent term is a nominal legal baseline that rarely reflects the commercial reality of a pharmaceutical product. While
The Math of Monopoly: Why a 20-Year Drug Patent Lasts Only 12 Years Read Post »
The Billion-Dollar Blind Spot in Pharmaceutical Strategy Every year, pharmaceutical executives sit in board meetings with revenue projections that quietly
Know Before the Cliff: How to Forecast Drug Patent Expiry Read Post »
Every major drug facing generic competition is a battlefield. The weapon of choice is not chemistry or clinical data—it is
Top Paragraph IV Litigation Trends and What They Mean for Pharma Read Post »
Sign in or create a free account to read this DrugPatentWatch article
